AI assistant
ZOONO GROUP LIMITED — Capital/Financing Update 2017
May 4, 2017
66124_rns_2017-05-04_cc86e1aa-447f-475b-86f4-950c201a74f7.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [65 x 70] intentionally omitted <==
Zoono Group Limited
ABN: 73 006 645 754 Level 3, 35 Lime Street Sydney NSW 2000
T: 02 8042 8481 E: [email protected] W: www.zoono.com
ASX RELEASE
5 MAY 2017
UPDATED CAPITAL STRUCTURE
Zoono Group Limited would like to advise that set out below is the updated capital structure table following completion of the raising of $10,000,000 under the Offer made in the Company’s Replacement Prospectus dated 14 March 2017.
| Fully Paid Ordinary Shares | Number | % |
|---|---|---|
| Existing Shares (Pre-Raise) | 8,314,425 | 5.10% |
| Offer (New Shares) | 50,000,000 | 30.67% |
| Acquisition Shares | 94,500,000 | 57.97% |
| Other Shares Issues | 10,197,402 | 6.26% |
| Total Shares | 163,011,827 | 100.00% |
| Free Float | 58,933,545 | 36.15% |
| Escrowed Shares | 104,078,282 | 63.85% |
For further information please contact:
Elissa Hansen Company Secretary [email protected] 0411 764 556
About Zoono:
Zoono specialises in the development, manufacture and global distribution of a suite of proven, long lasting and environmentally friendly antimicrobial solutions. It has developed products, including aerosol-based sprays, suited for skin care, surface sanitisers, treatment of acne and mould remediation. The products are based around the “Zoono Molecule”; a unique, antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould. It has proven efficacy, longevity and, importantly, it does not leach. Zoono products are currently sold in many countries.